Adipocyte Differentiation Protocol

The protocol is standard; the failures are in confluence and serum.

3T3-L1, the standard protocol

DayManipulationNotes
−2Seed 2–3 × 10⁴ cells/cm²Uniform density matters more than exact number
−1Grow to 2 days post-confluenceContact inhibition is part of the programme
0Induction: 0.5 mM IBMX, 1 µM dexamethasone, 10 µg/mL insulinIn 10% FBS, 2–3 days
2–3Insulin only, 10 µg/mL2 days
5Maintenance mediumRefresh every 2–3 days
8–12Mature: multilocular dropletsAssess, do not assume

Confluence is the variable that most often explains failure. Cells induced at 70% confluence differentiate poorly, and the reason is that contact inhibition and the first mitotic clonal expansion are part of the programme, not a technicality.

Human preadipocytes, which are not the same protocol

Parameter3T3-L1Human ASC
Induction length2–3 days3–7 days
IBMXRequiredOften required; some protocols omit
Dexamethasone1 µM1 µM, sometimes omitted
Insulin10 µg/mL1–10 µg/mL, longer
RosiglitazoneOptionalOften included
Time to mature8–12 days14–21 days
Differentiation efficiencyTypically 80–95%Typically 40–80%, donor-dependent

Caveat on donor variance. Human ASCs from different donors differ several fold in differentiation capacity. If the effect of a treatment is smaller than that spread, the experiment requires multiple donors as biological replicates; otherwise the comparison is between donors.

The cocktail components as experimental variables

ComponentConcentrationIntended actionConfound
IBMX0.5 mMPDE inhibition, raises cAMPBroad cAMP effects on metabolism and lipolysis
Dexamethasone1 µMGR agonist, induces C/EBPδSuppresses inflammation; alters lipolysis
Insulin10 µg/mLIGF1R/IR signallingSupraphysiological; desensitises insulin signalling
Rosiglitazone1 µMPPARγ agonistSelects a transcriptional programme; increases lipid capacity

Dexamethasone is the most consequential. It is present to drive differentiation and it also suppresses inflammatory signalling. A study of "glucocorticoid effects on adipocyte inflammation" that used a dex-containing induction protocol is measuring a second dose on an already-treated cell.

Important distinction. Insulin at 10 µg/mL is roughly 1,700 nM — far above any physiological concentration. Cells differentiated in it have downregulated insulin signalling, which matters when the readout is insulin-stimulated glucose uptake.

QC gates

GateThresholdMethod
Differentiation efficiency≥ 80% (3T3-L1); report for human ASCBODIPY-positive cells with ≥ 3 droplets, by imaging
Droplet morphologyMultilocular, uniformImaging; unilocular giant droplets suggest over-differentiation or a different phenotype
Adiponectin secretionDetectable, increasing with daysELISA, normalised to cell number
Insulin-responsive uptake≥ 1.5-fold over basal2-DG with a full insulin dose–response
Lipolytic response≥ 2-fold glycerol release with isoproterenolGlycerol assay
MycoplasmaNegativeMonthly

A culture that fails the first gate cannot be compared with one that passed: every downstream readout scales with the fraction of differentiated cells.

Readouts, and the normalisation problem

ReadoutNormalise toWhy
Lipid content (BODIPY area)Cell numberLipid per cell, not per well
Triglyceride massDNA or cell numberLipid loading changes protein per cell
Adiponectin, leptinCell numberProtein normalisation is confounded by lipid
Glycerol releaseCell number and timeRate, not amount
2-DG uptakeCell number; protein is acceptable hereTransport is per cell
UCP1Protein, plus respirationTranscript alone is insufficient

Readout note. Protein normalisation is the default in most labs and it is wrong for secreted adipokines: a lipid-loaded adipocyte has more total protein per cell and less secretion per cell, so a per-microgram value can fall while the per-cell value rises.

Lipolysis: glycerol versus fatty acids

MeasurementReportsLimitation
Glycerol releaseComplete hydrolysis of triglycerideInsensitive to partial hydrolysis and re-esterification
Free fatty acid releaseNet effluxIncludes partial products; affected by re-esterification and export
Both togetherThe balanceRequires both assays on the same well

A treatment that raises fatty acid efflux with unchanged glycerol is shifting re-esterification, not increasing hydrolysis. That is a different mechanism, and it is the one that matters for ectopic lipid deposition.

Troubleshooting by symptom

SymptomMost likely causeDiagnostic
Few droplets at day 8Induced before confluence; expired IBMX; high passageRe-seed and induce 2 days post-confluence; keep passage ≤ 10
Droplets in patchesUneven seeding densityMap confluence before induction
Cells detach during inductionIBMX toxicity at high density; serum lotLower IBMX to 0.25 mM; test a new lot
Abundant lipid, low adiponectinOver-differentiation; rosiglitazone effectMeasure both; include a no-rosiglitazone arm
No lipolytic responseDexamethasone carryover; receptor desensitisationWash before assay; run an isoproterenol dose–response
Spontaneous UCP1 inductionProlonged rosiglitazone; chronic cAMPRemove rosiglitazone at day 4; check basal cAMP

The second row explains most reports of "variable differentiation": density heterogeneity produces patches of differentiated and undifferentiated cells, and the population average moves with the ratio between them rather than with the treatment.

Failures that recur

  • • Induction at 70% confluence. Poor and variable differentiation.
  • • Differentiation efficiency unreported. All downstream values are scaled by it.
  • • Dexamethasone confound ignored in inflammation studies.
  • • Insulin at 10 µg/mL used, then insulin sensitivity measured. The cells are desensitised.
  • • Protein normalisation for secreted factors.
  • • Passage number too high. 3T3-L1 loses differentiation capacity after ~10 passages.
  • • Serum lot changed mid-experiment.

Where this connects

  • • Adipocyte models article supplies the model-choice logic and the beige evidence standard.
  • • Lipid pillar supplies the storage and lipolysis chemistry.
  • • Insulin resistance article supplies the dose–response requirement when uptake is the readout.

Scientific interpretation and experimental design

  • • Confluence is a variable. Induce at 2 days post-confluence.
  • • Report differentiation efficiency. It scales every result.
  • • Treat dexamethasone as a treatment. It is not a neutral ingredient.
  • • Normalise secretion to cell number.
  • • Measure glycerol and fatty acids for lipolysis claims.
  • • Use multiple donors for human ASC.
  • • Record passage. Capacity declines with it.

Selected references for further reading

  • • Green H, Kehinde O. An established preadipose cell line and its differentiation in culture. Cell. 1975;5:19–27.
  • • Zebisch K, Voigt V, Wabitsch M, Brandsch M. Protocol for effective differentiation of 3T3-L1 cells to adipocytes. Analytical Biochemistry. 2012;425:88–90.
  • • Lefterova MI, Lazar MA. New developments in adipogenesis. Trends in Endocrinology and Metabolism. 2009;20:107–114.
  • • Schweiger M, et al. Measurement of lipolysis. Methods in Enzymology. 2014;538:171–193.

Related Products

Product name Cat.No. Species Gene ID
PBRM1 Knockout A-549 Cell Line EDJ0001-K01 Human 55193 Details Get a Quote
YTHDC1 Knockout A-549 Cell Line EDC07652 Human 91746 Details Get a Quote
TP53 Knockout HCT 116 Cell Line EDC07854 Human 7157 Details Get a Quote
Sirt2 Knockout MH-S Cell Line EDJ-KQ78173 Mouse 64383 Details Get a Quote
TFE3 Knockout KGN Cell Line EDJ-KQ48 Human 7030 Details Get a Quote
Stub1 Knockout MB49 Cell Line EDJ-KQ53 Mouse 56424 Details Get a Quote
ARID1A Knockout SNK-6 Cell Line EDJ-KQ64 Human 8289 Details Get a Quote
Tet1 Knockout Kupffer Cell Line EDJ-KQ88 Mouse 52463 Details Get a Quote
NR1H3 Knockout HEK293T Cell Line EDJ-KQ109 Human 10062 Details Get a Quote
NR1H2 Knockout HEK293T Cell Line EDJ-KQ110 Human 7376 Details Get a Quote
RPS6KB2 Knockout HEK293 Cell Line EDJ-KQ125 Human 6199 Details Get a Quote
SMAD6 Knockout HEK293 Cell Line EDJ-KQ126 Human 4091 Details Get a Quote
JUN Knockout HEK293 Cell Line EDJ-KQ176 Human 3725 Details Get a Quote
JUN Knockout HEK293T Cell Line EDJ-KQ184 Human 3725 Details Get a Quote
ALKBH5 Knockout HEK293 Cell Line EDJ-KQ186 Human 54890 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: